Gene-Edited immune cells take on Hard-to-Treat blood cancers
Disease control
Completed
This study tested a new treatment called CTX131 for adults with blood cancers (lymphoma or leukemia) that came back or didn't respond to standard therapy. CTX131 uses CRISPR gene editing to create donor immune cells that target a protein called CD70 on cancer cells. The goal was …
Phase: PHASE1, PHASE2 • Sponsor: CRISPR Therapeutics • Aim: Disease control
Last updated May 12, 2026 13:42 UTC